Natera, Inc. (NASDAQ:NTRA) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 123,593 shares of the medical research company's stock after selling 12,538 shares during the quarter. Hsbc Holdings PLC owned about 0.09% of Natera worth $19,573,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after buying an additional 879,463 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Natera by 15.7% in the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after purchasing an additional 142,201 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Natera by 40.0% during the 4th quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock worth $243,604,000 after purchasing an additional 439,540 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now owns 143,768 shares of the company's stock, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 182,621 shares of company stock worth $27,727,077 over the last 90 days. Company insiders own 7.60% of the company's stock.

Natera Stock Up 3.7 %

Natera stock traded up $5.65 during trading on Friday, reaching $157.01. 430,049 shares of the company's stock were exchanged, compared to its average volume of 1,376,728. The company's 50-day moving average is $146.92 and its two-hundred day moving average is $153.99. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The firm has a market cap of $21.23 billion, a price-to-earnings ratio of -89.19 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. On average, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Royal Bank of Canada started coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. Piper Sandler boosted their price objective on shares of Natera from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Finally, Barclays decreased their target price on shares of Natera from $200.00 to $160.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $175.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.